Atossa Therapeutics, Inc.
corporate_fare Company Profile
Atossa Therapeutics, Inc. (NASDAQ:ATOS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ATOS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for ATOS spans 10-Q, 8-K, 424B5, DEF 14A.
Recent high-impact activity:
- Atossa Q3 Loss Narrows to $5.6M as Cash Falls to $20.6M
- Atossa Q3: Cash Falls to $20.6M, Going Concern Reaffirmed as Burn Hits $24.7M
- Atossa Executes CVR Deal: Shareholders Get 25% of Priority Review Voucher Proceeds
- Atossa Q2 2026: Cash Burn Accelerates, Going Concern Warning, but Clinical Progress Continues
- Atossa Reports Q2 2026 Results, Highlights (Z)-Endoxifen Progress in Rare Diseases and Breast Cancer
Financial Snapshot
Short Interest & Short Volume
7.59 days to coverFINRA reported short interest of 526,812 shares in ATOS as of the October 30, 2026 settlement, a 22.9% decrease from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 60.4% of ATOS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for ATOS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-12.
Capital Raise Finalized · Offering Priced at Premium
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →